First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma

STATUS

Recruiting
participants needed

78
sponsor

Sanofi

Send

Updated on 19 February 2024

See if I qualify

measurable disease

monoclonal antibodies

cell transplantation

multiple myeloma

bortezomib

lenalidomide

monoclonal protein

carfilzomib

daratumumab

thalidomide

refractory multiple myeloma

line of therapy

ixazomib

pomalidomide

proteasome inhibitor

immunotherapeutic agent

autologous hematopoietic stem cell transplant

Summary

Primary Objectives:

Dose Escalation Part A: To determine the maximum tolerated dose (MTD) of SAR442085 administered as a single agent in patients with relapsed or refractory multiple myeloma (RRMM), and determine the recommended Phase 2 dose (RP2D) for the subsequent Expansion Part B
Dose Expansion Part B: To assess the antitumor activity of single agent of SAR442085 at the RP2D in patients with RRMM

Secondary Objectives:

To characterize the safety profile of SAR442085
To characterize the pharmacokinetics (PK) profile of SAR442085 when administered as a single agent
To evaluate the potential immunogenicity of SAR442085
To assess preliminary evidence of antitumor activity in the Dose Escalation Part A

Description

Patient will continue to receive study medication until disease progression, unacceptable toxicity, withdrawal of informed consent, or other reason why investigator considers it appropriate to discontinue study medication. Once permanently discontinued, study medication cannot be restarted at later timepoint.

Details

Condition	Multiple Myeloma, Multiple Myeloma, Lymphoproliferative Disorder, lymphoproliferative disorders, lymphoproliferative disorders
Age	18-100 years
Treatment	SAR442085
Clinical Study Identifier	NCT04000282
Sponsor	Sanofi
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Participant must be at least 18 years of age or of the country's legal age of majority if the legal age is >18 years old, at the time of signing the informed consent
	Participant has given voluntary written informed consent
	Participant has been previousy diagnosed with multiple myeloma based on standard criteria
	Part A: (1) participant has received at least 3 prior lines of therapy for multiple myeloma, or at least 2 prior lines of therapy if at least 1 of those lines consisted of 2 or more multi-agent regimens (eg, multi-agent induction regimen with autologous stem cell transplantation, followed by maintenance regimen). (2) Prior therapy for multiple myeloma has included at least 1 proteasome inhibitor (bortezomib, carfilzomib, ixazomib), at least 1 immunomodulatory agent (lenalidomide, thalidomide, pomalidomide), at least 1 anti-CD38 monoclonal antibody and at least 1 steroid. (3) Participant had at least a minimal response (MR) to the anti-CD38 antibody containing regimen and had last dose of anti-CD38 monoclonal antibody at least 9 months prior to study entry, except the last cohort(s) of Part A who are anti CD38 nave
	Part B and the last cohort(s) of Part A: (1) participant has received at least 3 prior lines of therapy for multiple myeloma, or at least 2 prior line of therapy if at least 1 of those lines consisted of 2 or more multi-agent regimens (eg, multi-agent induction regimen with autologous stem cell transplantation, followed by maintenance regimen). (2) Prior therapy for multiple myeloma has included at least 1 proteasome inhibitor (bortezomib, carfilzomib, ixazomib), at least 1 immunomodulatory agent (lenalidomide, thalidomide, pomalidomide) and at least 1 steroid. (3) Prior therapy has not included an anti-CD38 monoclonal antibody
	Participant has myeloma disease progression on or after last therapy
	Participant must have measurable disease as defined as at least one of the following
	Serum M protein 0.5 g/dL (5 g/L)
	Urine M protein 200 mg/24 hours
	Serum FLC assay: Involved FLC assay 10 mg/dL (100 mg/L) and an abnormal serum
	FLC ratio (<0.26 or >1.65)
	A male participant must agree to use contraception during the intervention period and for at least 150 days after the last dose of study drug and refrain from donating sperm during this period
	A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies
	Not a woman of childbearing potential (WOCBP)
	A WOCBP who agrees to follow the contraceptive guidance during the intervention period and for at least 150 days after the last dose of study intervention
Exclusion Criteria
	Participant is diagnosed or treated for another malignancy within 3 years prior to enrollment, with the exception of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, superficial bladder carcinoma or low risk prostate cancer
	Participant has an Eastern Cooperative Oncology Group (ECOG) performance status score >2\
	Participant has a history of Chronic obstructive pulmonary disease (COPD) or asthma
	Participant has not recovered from adverse reactions to prior myeloma treatment or procedures (chemotherapy, immunotherapy, radiation therapy) to NCI CTCAE Grade 1 or baseline (exception: alopecia)
	Participant has congestive heart failure (New York Heart Association) Grade II; cardiac myopathy, active ischemia, or any other uncontrolled cardiac condition such as angina pectoris, clinically significant arrhythmia requiring therapy including anticoagulants, or clinically significant uncontrolled hypertension, QT interval corrected by the Fridericia method >480 msec (Grade 2)
	Participant has had acute myocardial infarction within 6 months before first dose of study medication
	Participant has ongoing sensory or motor neuropathy of National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade 3
	Participant has active autoimmune disease including autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura, inflammatory bowel syndrome, pneumonitis or any chronic condition requiring a higher corticosteroid systemic equivalent than prednisone 10 mg daily
	Known acquired immunodeficiency syndrome (AIDS) or related illnesses or human immunodeficiency virus (HIV) disease requiring antiretroviral treatment, or to have active hepatitis A, B (defined as a known positive hepatitis B surface antigen (HBsAg) result), or C (defined as a known quantitative hepatitis C [HCV] ribonucleic acid RNA results greater than the lower limits of detection of the assay or positive HCV antigen) infection
	Participant has positive Coombs test at baseline
	The above information is not intended to contain all considerations relevant
	to a patient's potential participation in a clinical trial

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

measurable disease

monoclonal antibodies

refractory multiple myeloma

immunotherapeutic agent

autologous hematopoietic stem cell transplant

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma